Google Übersetzer
Tiziana Life Sciences Ltd
About
1.48USD+0.02 +1.37%
Closed • Updated at 13:18 GMT+00:00Market Cap$175.90M
Volume576.4K
Beta-0.71
RSI54.78
Tiziana Life Sciences Ltd — investor relations, events, news, and company updates on 6ix.
Latest News
May 21 2026
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
May 19 2026
Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis
May 14 2026
Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab
Apr 16 2026
Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function
Apr 14 2026
Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress
Recent Videos
MS trial phase 2 enrollment complete - Tiziana CEO on the foralumab breakthrough
May 22, 2026
Tiziana Life Sciences show foralumab breakthrough for MS patients
May 22, 2026
16 abril 26. Noticias acciones biotecnológicas. Resumen diario. #Español #Shorts #diario $XBI #bio
Apr 16, 2026
Taming Smoldering MS
Jan 21, 2026
Community Chat
Ask AI
Try asking